Normolipidemic Dysglycemia in Type 2 Diabetes: Clinical and Biochemical Characteristics of a Cohort Free of Lipid-Lowering and Chronic Anti-Inflammatory Therapy
Hormone and Metabolic Research · 2026-08-01 · 58 (08) · 299-310
DOI: 10.1055/a-2901-3276 ↗Abstract
AbstractIn type 2 diabetes, hyperglycaemia usually clusters with atherogenic dyslipidaemia and low-grade inflammation; yet, these axes may dissociate in some patients. We aimed to estimate the prevalence of a normolipidemic dysglycemia phenotype in adults with type 2 diabetes and characterise its clinical–biochemical profile within an analytical window free of lipid-lowering and chronic anti-inflammatory/immunomodulatory therapy. In this retrospective, cross-sectional study, we analysed records of 1,046 adults aged 25–60 years with type 2 diabetes from a tertiary care hospital between 2020 and 2024. Individuals with other diabetes types, acute inflammatory conditions, malignancy, advanced organ failure and non-euthyroid status were excluded. Normolipidemic dysglycemia was defined as glycated hemoglobin≥64 mmol/mol with low-density lipoprotein cholesterol
EUVIMED